1 min read
Add as a preferred source on GoogleTiziana Life Sciences Shares Fall About 13% After Phase 2a Results
The company said its intranasal foralumab study met both primary endpoints in patients with non-active secondary progressive multiple sclerosis.
Tiziana Life Sciences Ltd (TLSA) shares fell about 13% Monday, Nov. 2, while the company reported that its Phase 2a intranasal foralumab study met both primary endpoints in a specific multiple sclerosis patient group.
The study evaluated patients with non-active secondary progressive multiple sclerosis. Shares were down about 13% as of 3:13 p.m. ET (20:13 UTC).
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.